Patients who are obese or overweight are frequently seen in cardiology for other conditions and weight reduction with GLP-1 RAs can be a useful tool in the cardiologist’s toolbox. Through this program, cardiologists will become more familiar with the data supporting the use of GLP 1 RAs in their patients, identify appropriate patients and potential barriers to adherence, and learn how they can more effectively utilize these therapies in their unique patient population.

CME/CE Accreditation Information

Patients who are living with obesity or overweight may seek care with an endocrinologist for other comorbidities, some of which may be directly linked to their weight. Weight reduction and management using pharmacotherapy, including GLP-1 RAs, can be a useful strategy to help patients improve not only their weight but also their metabolic health. Through this program, endocrinologists will gain a deeper understanding of how they can appropriately select patients who may benefit from GLP-1 RAs, especially if they have other comorbidities, and apply clinical trial findings to everyday patient care. They will also enhance their understanding of strategies which can improve both patient adherence and payor authorization/approval.

CME/CE Accreditation Information

Women frequently rely on their OB/GYN as their primary source of healthcare, particularly during their reproductive years. Many of these individuals may be living with overweight or obesity, placing the OB/GYN in a uniquely positioned and trusted role to support healthy weight management and broader metabolic health goals. Pharmacotherapy—including GLP-1 receptor agonists—can be an important tool within a comprehensive, patient-centered approach. Through this program, OB/GYNs will develop a deeper understanding of how to appropriately identify candidates for GLP-1 RA therapy across different stages of the lifespan and will learn strategies to improve patient access, streamline documentation, and optimize payor authorization and approval.

CME/CE Accreditation Information

Patients who are obese or overweight are more likely to require joint replacement surgery than their normal weight peers; however, higher BMIs also substantially increase the risks of orthopedic surgery. This increased risk often leads to orthopedic surgeons requiring that their patients lose weight and obtain a BMI of <40 kg/m2 before proceeding with surgery. In previous years, bariatric surgery may have been the only feasible option for these patients, but now anti-obesity medications, like GLP-1 receptor agonists, are a valid alternative and may be more palatable for patients. Through this program, orthopedic surgeons will gain a deeper understanding of how they can appropriately select patients who may benefit from GLP-1 RAs and enhance their understanding of strategies which can improve patient access and adherence.

CME/CE Accreditation Information

Welcome to this curriculum on the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This program is designed to provide you with the latest strategies for accurately diagnosing, staging, and treating GEP-NETs by integrating pathological grading with advanced imaging and novel systemic therapies. This activity emphasizes a collaborative approach, encouraging multidisciplinary care coordination to personalize treatment plans and optimize outcomes for patients with this complex disease.

CME/CE Accreditation Information

Welcome to our comprehensive learning program on screening, diagnosing, and managing IgA nephropathy (IgAN). This program aims to provide you with a deep understanding of screening techniques, referral procedures, treatment selection, drug distribution and safety and monitoring requirements in IgAN management. Furthermore, this activity encourages care coordination between interdisciplinary team members to improve the co-management of patients with IgAN.

CME/CE Accreditation Information

This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HR+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information